Fortis Healthcare Shares Soar Over 6% as IHH Gets SEBI Open Offer Approval

In a major regulatory development, Fortis Healthcare Ltd (FHL) on October 3, 2025, announced that the Securities and Exchange Board of India (SEBI) has granted approval to IHH Healthcare Berhad to proceed with its long-awaited open offer for Fortis Healthcare and its subsidiary Fortis Malar Hospitals Ltd. The move marks a significant breakthrough in the years-long acquisition process, initially announced in 2018.

SEBI Clears IHH’s Open Offer After Seven Years

According to a filing, Fortis confirmed receiving a communication dated October 1, 2025, from SEBI approving IHH’s request to move ahead with its mandatory open offers. The announcement was simultaneously made by IHH Healthcare Berhad on the Bursa Malaysia, the Malaysian stock exchange.

Under the approved transaction, IHH, through its wholly owned subsidiary Northern TK Venture Pte Ltd, had earlier subscribed to 235,294,117 new equity shares of ₹10 each via preferential allotment. The acquisition also includes a mandatory open offer for 197,025,660 equity shares, representing 26.10% of Fortis Healthcare’s expanded voting share capital, and an additional open offer for 4,894,308 fully paid-up shares, or 26.11% of Fortis Malar Hospitals’ shareholding.

Regulatory Trail and Corporate Response

The latest regulatory nod follows a series of filings by IHH with Bursa Malaysia, referencing earlier announcements made between July 2018 and May 2025. The open offer had been on hold pending judicial and regulatory reviews since the original December 17, 2018, filing.

Fortis, in its statement signed by Company Secretary and Compliance Officer Satyendra Chauhan, said it would continue to keep both stock exchanges informed of any material developments. The company’s registered office is located at Fortis Hospital, Sector 62, Mohali, while its corporate office operates from Unitech Business Park, Gurgaon, Haryana.

IHH’s Strategic Intent and Market Impact

IHH Healthcare, registered in Malaysia, said the SEBI approval paves the way for it to strengthen its India operations. The company, a global leader in healthcare delivery, intends to deepen its strategic footprint through its Fortis acquisition. IHH will also continue to make updates to Bursa Malaysia as new developments occur in connection with the open offer.

This regulatory green light marks a pivotal step toward integrating the two healthcare groups, ensuring operational synergies and bolstering investor confidence in the Indian hospital sector, which has seen steady consolidation in recent years.

Read More: Apollo, Max Healthcare, Yatharth, Other Hospital Share Price Rise Up to 4% on CGHS Revamp Impact!

Fortis Healthcare Share Price Performance 

As of October 6, 2025, at 1:36 PM, Fortis Healthcare share price is trading at ₹1,045 per share, reflecting a gain of 6.59% from the previous closing price. Over the past month, the stock has gained by 10.83%.

Conclusion

With SEBI’s approval in place, the IHH-Fortis transaction, one of India’s most closely watched healthcare acquisitions, is finally set to move forward. The deal not only reaffirms IHH’s long-term commitment to India’s healthcare market but also signals a renewed phase of regulatory clarity and investor optimism for the country’s hospital industry.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.